TCR-T Product Analysis and Patient Monitoring

The IsoCode chip and IsoPlexis software combine to detect engineered T-cell therapy mechanism, including source of patient response and relapse, and elucidate cell-immunotherapy-driven efficacy and sources of inflammation. Adoptive cell transfer (ACT) of genetically engineered T cells expressing cancer-specific T-cell receptors (TCR) is a promising treatment in cancers such as melanoma. The IsoPlexis platform enables an in-depth investigation of the in vivo functional activity and dynamics of transferred cells. Past analysis using the IsoCode chip has revealed the coordinated functional dynamics of the adoptively transferred, as well as endogenous, T cells, and the importance of highly functional T cells in dominating the antitumor immune response.

IsoCode Data

Figure 1: IsoPlexis’ superior tracking used single-cell polyfunctional strength to monitor melanoma patients and predict relapse (Ma 2013).

Figure 2: CTL polyfunctional diversity analysis from healthy and metastatic melanoma donors. (Ma 2011).

Publications

Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, Chmielowski B, Economou JS, Comin-Anduix B, Ribas A, and Heath JR. Multifunctional T Cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy. Cancer Discovery, 3, 418 (2013).

Ma C, Fan R, Ahmad H, Shi Q, Comin-Anduix B, Chodon T, Koya RC, Liu CC, Kwong GA, Radu CG, Ribas A, and Heath JR. A Clinical Microchip for Evaluation of Single Immune Cells Reveals High Functional Heterogeneity in Phenotypically Similar T Cells. Nature Medicine, 17, 738-743 (2011).

Lu Y, Xue Q, Eisele MR, Sulistijo E, Brower K, Han L, Amir ED, Pe’er D, Miller-Jensen K, and Fan R. Highly Multiplexed Profiling of Immune Effector Functions Reveals Deep Functional Heterogeneity in Response to Pathogenic Ligands. Proc. Natl. Acad. Sci., 112 (7), 607-615 (2015).

Lu Y, Chen JJ, Mu L, Xue Q, Wu Y, Wu PH, Li J, Vortmeyer AO, Miller-Jensen K, Wirtz D, and Fan R. High-throughput Secretomic Analysis of Single Cells to Assess Functional Cellular Heterogeneity. Analytical Chemistry, 85 (4), 2548– 2556 (2013).

Local Dream Team Develops Cancer Treatment That's Saving Lives. A dream team of Caltech and UCLA scientists and doctors have created a treatment that's giving hope to cancer patients who once had none. The medication was developed by chemistry professor James Heath and his lab at Caltech in Pasadena, who work day and night, to help UCLA oncologist Antoni Ribas try to cure his incurable cancer patients.

Immune-Cell Therapy could Strengthen Promising Melanoma Treatment. A new study of genetically modified immune cells by scientists from UCLA and the California Institute of Technology could help improve a promising treatment for melanoma, an often fatal form of skin cancer.

Get the Picture for Personalized Medicine: Microchip Platform Can Create Movie of the Immune System During the Course of Treatment. Dr. James Heath and his colleagues at the California Institute of Technology have developed an enabling microfluidic technology called the Single Cell Barcode Chip (SCBC). The SCBC is currently being used in a melanoma clinical trial where researchers are engineering patients’ immune systems to attack their own cancer. 

Improving Health Assessments with a Single Cell. Research led by scientists from the California Institute of Technology (Caltech) has shown that a new generation of microchips developed by the team can quickly and inexpensively assess immune function by examining biomarkers—proteins that can reflect the response of the immune system to disease—from single cells.

Contact us to find out more about how IsoPlexis can help your organization.